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Paclitaxel is a successful anti-cancer drug that kills cancer cells in two-dimen-
sional culture through perturbation of mitosis, but whether it causes tumour
regression by anti-mitotic actions is controversial. Drug candidates that specifi-
cally target mitosis, including inhibitors of kinesin-5, AurkA, AurkB and Plk1,
disappointed in the clinic. Current explanations for this discrepancy include
pharmacokinetic differences and hypothetical interphase actions of paclitaxel.
Here, we discuss post-mitotic micronucleation as a special activity of taxanes
thatmight explain their higher activity in solid tumours.We reviewdata show-
ing that cells which exit mitosis in paclitaxel are highly micronucleated and
suffer post-mitotic DNA damage, and that these effects are much stronger
for paclitaxel than kinesin-5 inhibitors. We propose that post-mitotic micro-
nucleation promotes inflammatory signalling via cGAS–STING and other
pathways. In tumours, this signalling may recruit cytotoxic leucocytes,
damage blood vessels and prime T-cell responses, leading to whole-tumour
regression. We discuss experiments that are needed to test the micro-
nucleation hypothesis, and its implications for novel anti-mitotic targets and
enhancement of taxane-based therapies.
1. Introduction
From the early 1990s to the mid-2010s, the mitosis field engaged in a grand exper-
iment, to identifyproteins other than tubulin that are essential formitosis inhuman
cells, develop clinical grade small molecule inhibitors and test them for anti-cancer
action in man. The hope was for broad-spectrum anti-cancer drugs lacking the
neurotoxicity of taxanes. The first two arms were highly successful, and the field
is now blessed with potent and specific inhibitors of several essential mitosis pro-
teins including two kinesins (kinesin-5, CenpE) and three kinases (AurkA, AurkB
and Plk1). The clinical armwasmuch less successful.Most compounds lacked effi-
cacyat the toxicity limit,whichwasmostly set byneutropenia or gut toxicity [1–3].
This clinical failure, across multiple mitosis-specific targets, sharply decreased
pharmaceutical company interest in targeting mitosis. Its causes have been
reviewed, with different authors focusing on the low proliferation rate in cancer
cells [4,5] or differential pharmacodynamics (PD) [6].
The clinical failure of mitosis-specific drugs tested to date stands in stark con-
trast with the success of drugs that target microtubules, which include vinca
alkaloids, taxanes, ixabepilone and eribulin. All these drugs perturb mitosis as
their primary cytotoxic action in two-dimensional tissue culture, but whether
this is their therapeutic action in patients is controversial [4–6]. The purpose of
this review is to advance a hypothesis that is new to our knowledge, that the suc-
cess of taxanes in solid tumour treatment is due to their ability to induce multiple
micronuclei in cells that pass through mitosis in the presence of drug, which we
will term ‘micronucleation’. The mitosis-specific drugs tested to date exhibit
weaker micronucleation activity, which might explain their clinical failure.
Micronuclei are small nuclei containing one or a few chromosomes that
form due to mitotic chromosome segregation errors. Individual misplaced
& 2017 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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chromosomes recruit a nuclear envelope during telophase, and
once formed, micronuclei typically do not fuse with the main
nucleus. Paclitaxel induces dramatic segregation errors, lead-
ing to partitioning of the genome into many small nuclei
that we term ‘micronucleation’. This effect was noted in early
cytological studies of taxane action in two-dimensional culture,
particularly at low drug concentrations that do not pro-
mote mitotic arrest [7,8]. We revisit it in the light of recent
discoveries that micronuclei undergo dramatic DNA damage
[9] and nuclear envelope rupture [10], and can activate
the pro-inflammatory cGAS–STING pathway [11,12]. Pro-
inflammatory signalling has the potential to cure tumours
[13], and direct activation of the cGAS–STING pathway by
small molecule STING agonists eliminates solid tumours in
mice [14,15]. Putting all these data together, we propose that
inflammatory signalling, caused by micronucleation, plays a
central role in taxane action in tumours (figure 1c), and we
will discuss this idea in detail below.
Tumour inflammation, and its role in therapy, is a hugely
complex area that we will only touch on here. Our main goal
is to draw attention to micronucleation as an underappreciated
discriminating factor between taxanes and mitosis-specific
drugs, and to review recent data on activation of inflammatory
pathways by damage to the cell nucleus. We hope to open a
new line of discussion around taxane action and potential
novel cancer targets in mitosis. We emphasize that our model
is speculative, that we respect alternative viewpoints and that
more data are needed to decide these complex issues.
2. How do taxanes work in solid tumours?
Taxanes are among the most important drugs for solid tumour
treatment, and their clinical activity is still being optimized.
They bind to microtubules and stabilize the lattice, which inhi-
bits dynamic instability and promotes ectopic nucleation. Two
main models have been advanced to explain their anti-tumour
activity. Figure 1a illustrates the standard anti-mitotic model,
in which perturbation of mitosis causes cell-autonomous death
of the dividing cell. This is the predominant action in tissue cul-
ture [6,21–23]. High taxane concentrations arrest dividing cells
inmitosis bypreventing silencingof the spindleassembly check-
point (SAC). Subsequent behaviour is highly variable between
cell lines and individual cells. Arrested cells can die insidemito-
sis, or slipout bycyclinBdegradation.Aftermitotic exit they can
die, undergo senescence or re-enter the cell cycle progression.
Mitotic arrest is not necessary for mitosis-dependent cell
death. Paclitaxel promotes chromosome mis-segregation at
concentrations too low to cause mitotic arrest, which can lead
to late cell death [7,8]. This actionmight be particularly relevant
in tumours as thedrugconcentrationdecreasesover time follow-
ing a dose [24]. The clinical relevance of the anti-mitotic model
was strongly criticized from the perspective that the slow
proliferation rate in solid tumours is inconsistent with any
model where only cells that divide in drug are killed [4].
Figure 1b illustrates the main alternative proposed by Fojo
and others. In this model, taxanes act on interphase cells, e.g.
to perturb nucleus–cytoplasm trafficking [20,25] or MAPK
signalling [18,19], and this leads to cell-autonomous death.
This interphase killing model naturally accounts for the clinical
difference between taxanes and mitosis-specific drugs. The
main deficiency we see with this model is the lack of definitive
experimental systems where stabilization of interphase microtu-
bules causes death of non-dividing cancer cells. Many studies
have investigated alternative mechanisms of cell killing in two-
dimensional cultures, butmost are cloudedby failure to critically
discriminate mitosis-dependent versus -independent actions.
Time-lapse imaging is arguably the best way to do this [16].
Figure 1c proposes an alternative ‘inflammatory micronu-
cleation’ model that is new to our knowledge, though related
to other recent proposals [22,24]. It highlights the well known,
but underappreciated, mitosis-dependent micronucleating
activity of taxanes, and proposes inflammatory signalling to
amplify signals from a small fraction of dividing cells to elimin-
ate thewhole tumour. It makes multiple untested assumptions,
andmust be considered speculative. The central propositions of
this model are: (i) micronucleation is a special action of taxanes
and epothilones on dividing cells that is not sharedwith current
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Figure 1. Three models for the anti-tumour actions of paclitaxel (illustration by T.J.M.). (a) Anti-mitotic actions that cause cell-autonomous death via mitotic arrest
or chromosome mis-segregation. This well-characterized action accounts for essentially all cell killing in two-dimensional cell culture and is shared with mitosis-
specific drugs [16,17]. (b) Interphase actions that cause cell-autonomous death of non-dividing cells. Proposed pathways include activation of MAPK signalling
[18,19] and inhibition of cytoplasm–nucleus trafficking [20]. Mitosis-specific drugs lack these actions. (c) New model for whole-tumour action via inflammatory
micronucleation. Perturbation of mitosis and cytokinesis by taxanes generates G1 cells with multiple micronuclei [7]. Small micronuclei are coloured orange to signify
possible DNA damage [9] and cGAS recruitment. These effects in micronuclei activate inflammatory signalling, causing secretion of inflammatory cytokines and
chemokines that promote whole-tumour regression in sensitive patients.
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mitosis-specific drugs, (ii) micronucleation promotes inflamma-
tory signalling and (iii) inflammatory signalling from a subset
of cells that pass through mitosis in drug promotes whole-
tumour regression, at least in sensitive patients. Micronucleation
can occur at taxane concentrations well below those required
for mitotic arrest, and micronucleated cells can persist for
days. These effects will likely lead to gradual accumulation of
multi-nucleated cells in a drug-treated tumour, unlike apoptotic
cells, which are rapidly cleared by phagocytosis. Below, wewill
review evidence that leads us to propose the micronucleation
model, suggest experiments to test it and briefly discuss impli-
cations for novel anti-mitotic targets and taxane pharmacology.
3. Why did current mitosis-specific drugs
fail in the clinic?
All available data on drugs that inhibit kinesin-5, CenpE,
AurkA, AurkB and Plk1 attest that they can cause lethal pertur-
bation of cell division bydirect anti-mitotic actions (figure 1a). If
they were present in patients at sufficient concentration for suf-
ficient time, they should eliminate tumours by this mechanism.
The problem is therapeutic index. All these proteins are equally
required for mitosis in normal cells, and cell division occurs
more frequently in the bone marrow and gut than in solid
tumours [4,5]. Promyelocytes in the bonemarroware the fastest
dividing cell population in adults, which likely explains why
neutropenia was the dose-limiting toxicity of many of the
drug candidates that specifically target mitosis [3]. The need
to avoid bone marrow and gut toxicity presumably limited
drug exposure in patients to below that required to cause
tumour regression. Fojo and co-workers [4] argued that given
the low proliferation rate in solid tumours compared to
normal tissues, we cannot expect useful therapeutic index
from purely anti-mitotic actions of any drug. This argument is
strong, but it assumes that drug-induced cell death is cell-auton-
omous. We could rescue the anti-mitotic hypothesis if taxane
action on mitosis causes extensive bystander killing, while the
action of mitosis-specific drugs on mitosis does not [5].
The clinical failure of the mitosis-specific drugs raises
serious criticisms of the assays that were used to advance
them to the clinic. Fojo and co-workers [4] emphasized that
two-dimensional cell cultures and mouse tumour models all
exhibit cell division rates that are much higher than human
tumours, and thus tend to over-predict the efficacy of drugs
with cell cycle targets.We agree, but herewe focus on adifferent
issue, lack of measurements of inflammatory signalling during
drug development. If solid tumours are eliminated by the con-
sequences of this signalling, thenmeasuring it in culture would
better predict tumour responses than measuring cell death or
inhibition of proliferation. Another criticism is that mouse
studies appear to have systematically under-predicted the
bone marrow toxicity of mitosis-specific drugs, and rats may
provide a better model for this likely dose-limiting toxicity [26].
4. Paclitaxel and kinesin-5 inhibitors differ
in post-mitotic micronucleation and DNA
damage
It is instructive to compare the cellular actions of taxanes to
mitosis-specific drugs in pre-clinical models to try and
understand why paclitaxel is much more active as a solid
tumour treatment in man. We will focus only on kinesin-5
inhibitors (K5Is) for simplicity. To what extent our arguments
extend to inhibitors of mitotic kinases is an important open
question. K5Is were the first mitosis-specific drugs to be
tested in man, led by ispinesib from Cytokinetics/GSK [27].
K5I-treated cells arrest in mitosis with monopolar spindles
[28], and most K5Is are extremely specific because they
target allosteric pockets in the motor domain [29]. Our group
and others directly compared the cellular actions of paclitaxel
to K5Is in cell culture and mouse tumour models [17,30–33].
Differential cell killing during mitotic arrest is likely not a
discriminator between paclitaxel and K5Is. Both drugs arrest
cells in mitosis by preventing silencing of the same SAC.
Arrested cells eventually exit mitosis by degradation of cyclin
B without SAC inactivation, in a process termed mitotic slip-
page [34]. The duration of mitotic arrest and the fraction of
arrested cells that die in mitosis versus those that slip out of
mitosis were similar between paclitaxel and a K5I when the
two drugs were compared at high concentrations that
promoted strong mitotic arrest [17].
Interphase action is certainly a discriminator, though its
clinical significance is unclear. Paclitaxel promotes stabiliz-
ation and ectopic bundling of microtubules throughout the
cell cycle, while the only known function of kinesin-5
(a.k.a. Kif11, Eg5, KSP) is to separate the poles of the mitotic
spindle. The unresolved questions are if, and how, taxanes
kill non-dividing cancer cells in tumours, and the extent to
which interphase killing contributes to therapy. Potential
interphase actions of paclitaxel were reviewed briefly above;
the focus of this review is on mitosis-dependent actions.
Pharmacokinetics (PK) and PD may be discriminators.
Paclitaxel tends to persist in solid tumours for many days, pre-
sumably bound tomicrotubules [6,35], while K5Is exhibit more
ordinary pharmacology [1]. Paclitaxel causes chromosome seg-
regation errors and micronucleation after mitotic exit at low
concentrations that do not cause mitotic arrest [24,36]. These
low-concentration effects, combined with prolonged residence
of the drug in tumours, may well contribute to the higher
clinical efficacy of taxanes.
Micronucleation is the discriminator we focus on in this
review. As pointed out by Wilson and co-workers [7], cells that
pass through a paclitaxel-inhibited mitosis in two-dimensional
culture tend to exhibit multiple micronuclei, a morphology we
refer to as ‘bunch of grapes’ nuclei (figure 2). Inmarked contrast,
cells that slip out of K5I-inhibited mitosis tend to have a single
large nucleus. Head-to-head comparison in two-dimensional
culture and a mouse tumour model noted much stronger
micronucleation after exit from mitosis in paclitaxel than a K5I
(figure 2). For cytological analysis of micronucleation, it is
important to distinguish it from apoptosis, because both cause
a multi-lobed appearance of the nucleus. Chromatin is much
more condensed during apoptosis, and apoptosis leads to cell
rounding and blebbing shortly followed by lysis (in culture) or
removal by phagocytosis (in tumours). Multi-nucleated cells,
by contrast, decondense their chromatin and they can persist
for days after exiting from a drug-treated mitosis.
Post-slippage DNA damage is another potentially
important discriminator that is mechanistically linked tomicro-
nucleation. Figure 3a shows data abstracted from papers where
we measured markers of apoptosis, mitosis and DNA damage
in parallel across four cell lines treated with saturating concen-
trations of paclitaxel versus a K5I [17]. The effects of the two
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drugs were very similar in lines that tend to undergo apoptosis
during mitotic arrest or shortly afterwards (HeLa, U2OS). Note
that apoptosis (marked by Parp1 cleavage) triggered strong
DNAdamage (markedbyPhos-H2AX)due toDNA fragmenta-
tion by CAD nuclease. Here, we draw attention to extensive
DNA damage that occurred in cells that exited mitosis in pacli-
taxel but did not initiate apoptosis, as is the case for A549 and
RPE cells at 48 and 72 h (red asterisks in figure 3). This DNA
damage signal was much stronger in paclitaxel than K5I (com-
pare red asterisks to blue circles). At the time we did not
understand its cause. In the light of new data on induction of
DNA damage in micronuclei [9], we hypothesize this pacli-
taxel-specific, post-slippage, non-apoptotic DNA damage was
caused by extensive micronucleation after slippage out of pacli-
taxel-treatedmitosis, followed bymicronucleus-triggeredDNA
damage. Consistent with this interpretation, figure 3b shows
cytological evidence for DNA damage in a micronucleated
cell from a more recent paper [33].
5. Paclitaxel micronucleation mechanism
Themechanisms bywhich paclitaxel promotes strongmicronu-
cleation have not been studied in detail, and warrant further
analysis. We suspect at least two effects are at play based on
published cytology (figure 4).Mitotic spindles tend to assemble
with multiple poles in paclitaxel, even at low drug concen-
trations that do not promote strong mitotic arrest [24]
(figure 4a). Ectopic poles are probably caused by ectopic micro-
tubule nucleation, followed by clustering of minus ends by
dynein and NUMA [39]. Kinesin-5 knockdown reduced micro-
nucleation by paclitaxel, suggesting that kinesin-5 helps keep
ectopic poles separated [33]. The presence of multiple spindle
poles presumably leads to separation of chromosomes intomul-
tiple groups at anaphase onset. When paclitaxel-treated cells
exit mitosis, they tend to exhibit ectopic cleavage furrows
(figure 4b,c) [37,38]. These likely partition chromosome clusters
into separate pockets of cytoplasm, keeping them separated
during the critical period for nuclear envelope reformation in
telophase. Ectopic furrows may result from recruitment of
the furrow-stimulating complexes CPC and centralspindlin to
Taxol-stabilized microtubule bundles [38,40]. Paclitaxel’s
combined effects of promoting multi-polar spindles and trig-
gering ectopic cleavage furrows are not shared with current
mitosis-specific drugs, and likely endow it with higher
micronucleation activity.
6. DNA damage and nuclear envelope
breakdown in micronuculei
Pioneeringwork fromPellman and co-workers [9] showed that
the DNA in micronuclei formed by chromosome segregation
errors tends to undergo extensive DNA damage, while the
main nucleus in the same cell is spared. They went on to
show this can account for the phenomenon of chromothripsis,
where single chromosomes are fragmented and rearranged
during cancer progression [41]. Separately, Hetzer and co-
workers [10] showed that micronuclei tend to undergo cata-
strophic nuclear envelope breakdown that exposes their
DNA to the cytoplasm. The relationship between these obser-
vations, and the mechanisms that induce them, is under
intense investigation. These observations were made in cells
with only one or a few micronuclei, but the data in figure 2
suggest that taxane-induced micronucleation also causes
extensive DNA damage.
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Figure 2. Nuclear morphology after exit from aberrant mitosis in paclitaxel versus K5Is. (a) DNA stained field of HT1888 cells in two-dimensional culture 36 h after
treatment with paclitaxel (100 nM) or a K5I (K858, 10 mM). Most cells have slipped out of drug-arrested mitosis at this time point. Note multiple micronuclei in paclitaxel
and mostly single nuclei in K5I. Taken from Nakai et al. [30]. (b) U2OS cells time-lapse imaged in two-dimensional culture in the presence of paclitaxel (150 nM) or a K5I
(EMD534085 1 mM). Top panels are phase-contrast images of single cells that have slipped out of mitotic arrest after approximately 30 h in drug. The bar graph shows
quantification of nuclei per post-slippage cell. Note multiple micronuclei in paclitaxel but not K5I. Taken from Zhu et al. [33]; note senior author Shi is an author of the
review. (c) Quantification of nuclear morphology in HT1080 xenograft tumours by quantitative intravital microscopy before, and 72 h after, drug treatment. Nuclei were
visualized with a transfected histone-CFP probe. Each pair of bars shows data from the same mouse before, and 3 days after, after a single drug dose. Ispinesib is a K5I,
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that the extent of mitotic arrest was similar in the three drugs, and that the microtubule drugs caused tumour regression, while the K5I did not. Taken from Chittajallu
et al. [32].
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7. Inflammatory signalling in
micronucleated cells
Figure 5 illustrates four candidate inflammatory pathways that
may be activated in micronucleated cells. This list is far from
exclusive, and other pathways likely remain to be discovered.
The top row in figure 5b illustrates nuclear export of DNA
fragments following DNA damage [42,43]. Once exported,
these fragments can bind to the cytosolic DNA sensor cGAS.
DNA binding triggers synthesis of the second messenger
2030cGAMP which binds to STING [44]. STING then activates
the TBK1–IRF3 pathway, leading to expression of inflamma-
tory cytokines and chemokines including interferons. The
second row illustrates cGAS activation by nuclear envelope col-
lapse, which is relatively frequent in micronuclei [10]. This
route to cGAS activation by micronuclei was recently impli-
cated in the response to tumours to DNA damaging drugs
and radiation [45,46]. Several other candidate nucleic acid sen-
sors might also recognize DNA after nuclear export or/and
nuclear envelope rupture [47]. The third row illustrates nuclear
export of the chromatin protein HMGB1, which occurs via
acetylation in response to DNA damage and other inflamma-
tory triggers. Extracellular HMGB1 acts as an alarmin to
activate inflammatory signalling [48], and was shown to pro-
mote anti-tumour inflammation in response to DNA damage
in a mouse model [49]. Extracellular HMGB1 has also been
implicated in response of human cancer to chemotherapy
[50], so it is an important candidate factor when considering
inflammatory responses to nuclear damage. The last row illus-
trates an interesting pathway by which tension in an intact
nuclear envelope promotes cPLA2 and 5-lipoxygenase acti-
vation, leading to secretion of pro-inflammatory leukotrienes.
This pathway was shown to mediate chemotaxis of leucocytes
towounds in zebrafish, where the triggerwas osmotic swelling
of nuclei at the wound margin [51]. Micronuclei might trigger
cPLA2 activation and inflammatory leukotriene release if their
envelope is under tension due to abnormally high surface
area/volume ratios.
Secretion of inflammatory cytokines by micronucleated
cells (figure 1c) conceptually resembles inflammatory signal-
ling by senescent cells that have entered the ‘senescence-
associated secretory phenotype’ (SASP) [22]. Data in recent
papers suggest that this similarity may extend to causal mech-
anisms. Induction of senescence by DNA damage, oncogenes
and ROS was shown to depend on cGAS–STING signalling
[52–54]. The trigger in each case was blobs of chromatin in
the cytoplasm of senescing cells that morphologically resemble
micronuclei without nuclear envelopes, but are thought to
form in a mitosis-independent manner, by extrusion from
interphase nuclei. These chromatin blobs presumably signal
in the same way as micronuclei whose envelopes have
ruptured (figure 5b, second row). The morphological and sig-
nalling similarities between micronucleated and senescent
cells revealed by these studies suggest that we might think of
taxanes as drugs that promote mitosis-dependent SASP, as
proposed by Cheng & Crasta [22].
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Figure 3. DNA damage signalling after slippage from drug-treated mitosis (a). Western blot analysis of apoptosis, mitosis and DNA damage in cells treated with
paclitaxel or a K5I. Four cell lines growing in two-dimensional culture were treated with paclitaxel (150 nM) or EMD534085 (500 mM). Cells are arranged in order of
apoptosis sensitivity, with HeLa most sensitive and RPE1 least. HeLa cells mostly died by apoptosis during mitotic arrest in both drugs. Note that apoptosis (scored
by Parp1 cleavage) causes extensive DNA damage via the CAD pathway, so all conditions where Parp1 is cleaved also exhibit DNA damage signalling. A549 and RPE1
cells mostly slipped out of mitotic arrest without dying—note lack of Parp1 cleavage. In those lines, paclitaxel promoted extensive DNA damage signalling at 48
and 27 h (red asterisks), while K5I did not (blue circles). Modified from Shi et al. [17]; note senior author Mitchison is an author of the review. This panel has been
modified from the primary publication. (b) Immunofluorescence of U2OS cells that have slipped out of mitotic arrest in paclitaxel versus K5I. The conditions are the
same as figure 2b. Note strong H2AX staining in paclitaxel-induced micronuclei. The K5I-treated cell also exhibits some DNA damage, probably caused by CAD
nuclease activity during prolonged mitotic arrest. Taken from Zhu et al. [33].
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8. From inflammation to whole-tumour
responses
Inflammation can drive carcinogenesis and help tumours grow.
Sufficiently strong inflammation can also destroy tumours.
Which effects dominate under particular conditions is an
intense current research topic. Untreated tumours are infiltrated
with diverse leucocytes at baseline, to an extent that varies
widely between patients [13]. Chemotherapy and radiation
cause large changes in leucocyte infiltration and stromal inflam-
matory signalling which can oppose, or promote, therapy
depending on the context [55]. Tumour-associated macro-
phages present at baseline tend to protect mouse tumours
from taxanes [56]. In human breast tumours, paclitaxel
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Figure 4. Paclitaxel promotes multi-polar spindles and ectopic cleavage furrows (a). Paclitaxel-treated mitotic MDA-MB-231 cells. Note multiple spindle poles in
many cells. Numbers refer to spindle pole count. Spindles with three or more poles predominated at paclitaxel concentrations above 10 nM. Taken from Zasadil et al.
[24]. (b) Time-lapse imaging of a dividing PtK cell in 10 mM paclitaxel. The SAC was slowly silenced in drug, and the cell progressed to cytokinesis. Note highly
abnormal cleavage, with multiple ectopic furrows, in the last frame. Numbers refer to elapsed time (h : min). Taken from Yang et al. [37]. (c) Telophase PtK2 cells
fixed and stained for DNA and myosin-II. In this experiment, the paclitaxel-treated cell (10 mM) was forced out of mitosis by inhibition of Mad2. Note formation of
multiple ectopic furrows that recruit myosin-II (arrows). Taken from Shannon et al. [38].
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caused a large influx of new macrophages, the extent of which
correlatedwith response to therapy [57]. Taxane-induced leuco-
cyte infiltration was also observed in a subset of mouse
syngeneic tumour models, where it again correlated with
strong responses [58]. Whether taxane-induced infiltrating leu-
cocytes play a causal role in tumour regression, protect cancer
cells or are merely cleaning up cell corpses killed by the drug
is unknown.
The best evidence that strong inflammatory signalling can
cause tumour regression comes from the therapeutic activity
of directly pro-inflammatory anti-cancer drugs. For example,
the TLR agonist imiquimod clears basal carcinomas in man
via local inflammation [59], and the STING agonist DMXAA
caused tumour regression in mice via vascular disruption
and immune activation [60]. Whether taxane-treated human
tumours contain sufficient multi-nucleated cells to drive a
therapeutically useful, whole-tumour inflammatory response
in an important open question.
9. Tumour selectivity
Taxane toxicities include neutropenia, alopecia, mucositis, der-
matitis and peripheral neuropathy, so their actions are far from
tumour-specific. However, they destroy solid tumours but not
normal tissues in sensitive patients, so they do have a useful
therapeutic index. None of the arguments above, or literature
proposals we are aware of, explain this selectivity. Micronu-
cleation alone does not help, because it should occur in
normal dividing cells in the bone marrow and gut by the
same mechanisms as in tumours, likely at a higher density
due to the higher proliferation rate. Perhaps cell cycle check-
points prevent progression to S-phase in micronucleated
normal cells, but not in drug-sensitive cancer cells, resulting
in more DNA damage-driven inflammatory signalling in
tumours. Alternatively, inflammatory responses may be
mis-regulated at the tissue-scale in tumours, e.g. tumour vascu-
lature may be hyper-sensitive to inflammatory cytokines. In
this case, similar inflammatory signalling by micronucleated
cells would only cause tissue-scale destruction in tumours.
The source of the therapeutic index in taxane chemotherapy
is a crucial unanswered question.
10. Testing the inflammatory
micronucleation model
The degree to which different anti-mitotic and microtubule-
targeting drugs promote micronucleation after mitotic
slippage has not, to our knowledge, been systematically
measured or compared except for the K5I comparisons cited
in figure 2. This should be straightforward in two-dimensional
culture using high content assays, and is feasible in tumour
models using histology and intravital microscopy [32]. We pre-
dict that taxanes promote more extensive micronucleation
that any current mitosis-specific drugs. Comparisons between
anti-microtubule drugs will also be interesting. Epothilone B
(a stabilizing drug) cause more micronucleation than discoder-
molide (a destabilizer) in one study [8]. The microtubule
destabilizing anti-cancer drug eribulin, which is approved for
breast cancer treatment, was intermediate between paclitaxel
and a K5I in promoting micronucleation in a mouse tumour
model (figure 2c), but the number of mice sampled was too
small for this to be a definitive conclusion.
A second important question is whether taxane-induced
micronucleation activates inflammatory signalling in cancer
cells, and if so, through which pathways. Obvious next steps
are to measure inflammatory signalling in cells that have been
micronucleated by taxanes, and test the effect of knocking out
key pathway components such as cGAS, HMGB1 and cPLA2.
An interesting possibility is that taxane-promoted interphase
microtubule reorganization might synergize with micronuclea-
tion to promote inflammatory signalling. Comparison between
drugs in these assays will require cell lines that do not undergo
apoptosis during mitotic arrest or immediately after slippage,
and may also depend on an intact cGAS–STING pathway,
both of which vary across cancer cell lines.
We then need to know if taxanes promote inflammatory sig-
nalling in mouse tumour models, and if so, whether it is
micronucleation-dependent, and whether it causes whole-
tumour regression.Amajorchallenge in this area isdevelopment
of syngeneic or humanized models that accurately predict
the immunobiology of human tumours, including response
of leucocyte populations and tumour vasculature to drug
perturbation [55].
Finally, and most important, will be to profile micronu-
cleation-dependent inflammatory signalling in cancer cells
from patients who do, and do not, respond to taxanes. As dis-
cussed below, selection against cGAS–STING-dependent
inflammatory signalling during cancer progression may be
a major factor shaping drug responses.
11. Novel targets in mitosis
Micronucleation is an unanticipated side effect of taxane action
on microtubules. Do other targets exist for deliberately trigger-
ing micronucleation? One candidate is the VRK1–BAF
pathway. BAF (a.k.a. BANF1) is a structural protein that med-
iates interaction between chromatin and nuclear envelope, and
it is regulated by VRK1 kinase. Depletion of VRK1 or BAF pro-
motes strong micronucleation of dividing cells [61,62]. It is
possible that a VRK1 or BAF inhibitor would cause tumour
regression via micronucleation as efficiently as paclitaxel, but
lack neurotoxic side effects. Systematic investigation might
reveal additional targets for micronucleation-promoting drugs.
12. Patient variation and drug resistance
Paclitaxel alone promotes tumour regression in approximately
half of drug-naive breast cancer patients [63], and similar
response variation is seen in other diseases. The cause of
patient-to-patient variation is unknown despite decades of
research. Relapsed disease is often refractory to further treat-
ment, and the mechanistic basis of acquired resistance is also
unclear. In cell culture, taxane resistance usually occurs by
upregulation of drug efflux pumps, but the relevance of this
mechanism in patients is unclear, and P-glycoprotein inhibi-
tors were not successful in the clinic [64,65]. An important
finding, in both mice and patients, is that the response of
drug-naive tumours to paclitaxel did not correlate with the
extent of mitotic arrest shortly after drug administration
[66,67]. This lack of correlation between a direct, cell-auton-
omous PD biomarker and tumour regression suggests that
response variation is often due to variation in pathways that
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act downstream of mitotic perturbation, such as inflammatory
signalling, more than to cell-autonomous factors such as tubu-
lin isotype or P-glycoprotein expression. Recent work showed
that cGAS and STING are required for senescence of pre-can-
cerous cells exposed to DNA damage or activated oncogenes,
and proposed that progression to cancer involves downregula-
tion or mutation of this pathway [52–54]. Selection for loss of
cGAS/STING signalling during cancer progression might
help explain patient-to-patient variation, and suggests bio-
markers for predicting high responders. Finally, we propose
that pharmacological amplification of residual cGAS/STING
signallingwill promote taxane responses, and combat acquired
resistance. One possible target for such a drug is ENPP1, the
only enzyme known to break down the cGAS product
2030cGAMP [68], but additional negative inputs could likely
be identified and targeted.
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